David E. Williams Enterprises launched

After a decade at Boston Consulting Group, David Williams founded a solo strategy consulting practice dedicated to entrepreneurial healthcare organizations. First client: Healinx (later RelayHealth), helping develop its webVisits business model ahead of its acquisition by McKesson.

Karen Donovan joins the practice

A former LEK colleague, Karen brought deep expertise in healthcare technology, services, and primary data collection and analysis.

MedPharma Partners formed

Williams and Donovan joined forces with Patrick Kager, a former BCG colleague and life sciences partner at Deloitte, to create a practice spanning healthcare and life sciences.

Health Business Blog launched

The first weblog focused on the business of healthcare, published every business day for 15 years. An early and influential voice in healthcare strategy and policy.

Medical device practice added

John Seus, a partner at A.T. Kearney, joined to lead the medical device practice, expanding the firm's life sciences capabilities.

Healthcare reform focus

As the ACA was debated and passed, the firm deepened its work on system transformation. David Williams served as committee chair for the ONC's Health IT programs, reviewing Regional Extension Centers, Beacon Communities, and statewide Health Information Exchanges.

Health Business Group brand launched

The firm rebranded from MedPharma Partners to Health Business Group, better reflecting its broad healthcare and life sciences focus while continuing to serve pharma and device clients.

HealthBiz Podcast launched

The Health Business Blog evolved into a weekly podcast format featuring CEO interviews with leaders of innovative healthcare companies. The firm's distributed workforce model, pioneered in the early 2000s, meant operations were largely unaffected by the COVID-19 pandemic.

Cybersecurity, RWE, and clinical trial expansion

HBG deepened its cybersecurity practice supporting PE firms and health systems, and expanded project work across real world evidence, decentralized clinical trials, health system analytics, and digital health. M&A diligence included sterile fill/finish and complex solid dose CDMOs. David Williams was quoted in the Boston Globe and NPR on major healthcare stories.

AI strategy becomes a core practice area

HBG launched AI strategy engagements for a leading drug reference database and an AI collaboration platform — among the first in the firm's history focused squarely on artificial intelligence. Growth strategy work spanned clinical stage biotech, pharmacy chains, nurse staffing, and homecare. M&A diligence covered clinical registries, specialty staffing, senior care, and behavioral health.

Expanded mid-market advisory across strategy and M&A

Client work spanned remote patient monitoring, pharmacy automation, clinical stage biotech launch strategy, and outsourced manufacturing services. M&A diligence included a nurse practitioner platform, precision health and genetic testing, and cheminformatics software. Board and retainer work continued with Credo Health, Clerio Vision, and a cardiopulmonary virtual specialty clinic.

AI consulting expands; HealthBiz merges with CareTalk

HBG advised clients on AI strategy, GLP-1 and metabolic biotech, CDMO roll-ups, and pharmacy services for safety net providers. Board and retainer engagements included Credo Health, Clerio Vision, and Chronicle Medical. The HealthBiz Podcast merged with CareTalk, broadening its audience and reach.

Focused on AI integration and supply chain resilience

HBG is advising clients on two of the most consequential shifts in healthcare and life sciences: the practical integration of AI into clinical and administrative workflows, and the reshoring of US drug manufacturing driven by supply chain resilience and tariff policy. The firm continues its work across strategy, M&A, and board service for mid-market healthcare and life sciences companies.